CancerDrs

Lung Cancer clinical trials in Delaware

9 actively recruiting lung cancer trials at 8 sites across Delaware.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in Delaware:
  • Beebe Medical Center — Lewes, Delaware
  • Beebe South Coastal Health Campus — Millville, Delaware
  • Delaware Clinical and Laboratory Physicians PA — Newark, Delaware
  • Helen F Graham Cancer Center — Newark, Delaware
  • Medical Oncology Hematology Consultants PA — Newark, Delaware
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Sites in Delaware:
  • Beebe South Coastal Health Campus — Millville, Delaware
  • Helen F Graham Cancer Center — Newark, Delaware
  • Medical Oncology Hematology Consultants PA — Newark, Delaware
  • Beebe Health Campus — Rehoboth Beach, Delaware
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally advanced or …

Sponsor: AstraZeneca
NCT ID: NCT06627647
Sites in Delaware:
  • Research Site — Newark, Delaware
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable gen…

Sponsor: AstraZeneca
NCT ID: NCT07291037
Sites in Delaware:
  • Research Site — Newark, Delaware
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the M…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06116682
Sites in Delaware:
  • Bayhealth Hospital Kent Campus — Dover, Delaware
  • Bayhealth Hospital Sussex Campus — Milford, Delaware
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side e…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT07154290
Sites in Delaware:
  • ChristianaCare Health System — Newark, Delaware
View on ClinicalTrials.gov →
Recruiting Academic/Other

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable) or is …

Sponsor: University of Rochester
NCT ID: NCT06073431
Sites in Delaware:
  • Beebe South Coastal Health Campus — Millville, Delaware
  • Helen F Graham Cancer Center — Newark, Delaware
  • Medical Oncology Hematology Consultants PA — Newark, Delaware
  • Christiana Care Health System-Christiana Hospital — Newark, Delaware
  • Beebe Health Campus — Rehoboth Beach, Delaware
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Delaware:
  • Massive Bio SYNERGY-AI site — Newark, Delaware
View on ClinicalTrials.gov →
Recruiting Industry

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

The objective of this study is to build a prospective cohort in patients with locally advanced or metastatic NSCLC with common EGFR mutations. In NPM-002, there will be standardized data collection at baseline, on-treatment and at disconti…

Sponsor: N-Power Medicine
NCT ID: NCT07028489
Sites in Delaware:
  • Bayhealth Cancer Center- Kent — Dover, Delaware
  • Bayhealth Cancer Center- Sussex — Milford, Delaware
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12